Valuation: CORESTEMCHEMON Inc.

Market Cap	97.37B 71.55M 62.93M 59.51M 53.98M 101M 6.87B 102M 713M 275M 3.5B 269M 263M 11.26B	P/E 2024	-3.45x	P/E 2025	-2.05x
Enterprise Value	128B 94.16M 82.81M 78.31M 71.03M 133M 9.04B 134M 938M 362M 4.61B 353M 346M 14.82B	EV / Sales 2024	4.76x	EV / Sales 2025	5.59x
Free-Float	81.23%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news: CORESTEMCHEMON Inc.

07-18	CORESTEMCHEMON Inc. Announces South Korea's MFDS Allows Neuronata-R to Remain on Market, Preserving Conditional Approval for Als Treatment	CI
12-18	Corestemchemon Advances Toward Als Stem Cell Commercialization with Regulatory Progress in Korea and Nsf-Backed U.S. Expansion	CI
25-09-21	CORESTEMCHEMON Inc.(KOSDAQ:A166480) dropped from S&P Global BMI Index	CI
25-09-18	Neuronata- Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway	CI
25-07-21	Corestemchemon to divest 2.7 billion won worth of own shares	RE
25-07-21	CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services	CI
25-05-29	Corestemchemon Announces Neuronata-R®? Stem Cell Therapy Shows Promise in Als Phase 3 Subgroup Analysis, Moves Toward Fda Accelerated Approval	CI
25-05-29	Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis	RE
25-05-07	Corestemchemon To Divest 3.4 Billion Won Worth Of Own Shares	RE
25-03-26	Corestemchemon To Divest 3.6 Billion Won Worth Of Own Shares	RE
24-09-22	CORESTEMCHEMON Inc.(KOSDAQ:A166480) added to S&P Global BMI Index	CI
24-03-25	CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	CI
24-03-21	CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor	CI

More news

Managers and Directors: CORESTEMCHEMON Inc.

Manager	Title	Age	Since
Gil-Ahn Yang CEO	Chief Executive Officer	70	-
Gwang-Soon Kwon PSD	President	54	-
Si-Hwan Song PSD	President	65	2000-07-31

Director	Title	Age	Since
Gyeong-Sook Kim BRD	Director/Board Member	61	2015-06-15
Si-Hwan Song BRD	Director/Board Member	65	2000-07-31
Gwang-Soon Kwon BRD	Director/Board Member	54	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CORESTEMCHEMON INC.	+3.29%	+6.04%	+22.08%	-65.27%	71.55M
LONZA GROUP AG	0.00%	+4.12%	+12.74%	+37.69%	49.06B
IQVIA HOLDINGS INC.	+0.22%	+0.40%	+50.91%	+37.06%	44.6B
REVOLUTION MEDICINES, INC.	-1.58%	+4.66%	+359.34%	+614.38%	43.24B
BEONE MEDICINES AG	+1.70%	+0.36%	+12.56%	+99.27%	41.73B
CELLTRION, INC.	+0.51%	-1.71%	+5.18%	+46.87%	29.93B
MEDPACE HOLDINGS, INC.	-0.48%	-1.32%	+23.98%	+150.01%	17.19B
TEMPUS AI, INC.	+0.08%	+9.03%	+8.41%	-	15.35B
EUROFINS SCIENTIFIC SE	-2.39%	-2.68%	+26.38%	+43.63%	15.54B
ASCENDIS PHARMA A/S	+1.97%	-3.17%	-	-	15.11B
Average	+0.28%	+2.22%	+57.95%	+120.45%	27.18B
Weighted average by Cap.	+0.02%	+2.26%	+78.16%	+161.02%

See all sector performances

Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-28	₩2,195.00	+3.29%	143,189
26-09-23	₩2,125.00	+2.66%	99,187
26-09-22	₩2,070.00	0.00%	74,305

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 2026-09-28			5-day change	1st Jan Change
2,195.00 ^KRW	+3.29%		+6.04%	+18.78%

1 day	+3.29%
1 week	+6.04%
Current month	+4.52%
1 month	+7.60%
3 months	+10.41%
6 months	-13.41%
Current year	+18.78%

1 week	2,035	2,285
1 month	1,987	2,400
Current year	1,642	6,100
1 year	1,014	6,100
3 years	1,014	15,610
5 years	1,014	20,950
10 years	1,014	34,350

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
5/2/25	Tae-Yong Lee	Sell	Chief Technology Officer	64,262	0.1955%
5/2/25	Gwang-Soon Kwon	Sell	Chairperson	151,072	0.4596%
10/7/24	Ryeong Lee	Others		1,875	0.0057%	-

	2024	2025
Net sales	28.76B 21.14M 18.59M 17.58M 15.94M 29.94M 2.03B 30.12M 210M 81.29M 1.04B 79.35M 77.64M 3.33B	20.16B 14.81M 13.03M 12.32M 11.17M 20.99M 1.42B 21.11M 148M 56.97M 726M 55.62M 54.41M 2.33B
Net income	-26.25B -19.29M -16.97M -16.04M -14.55M -27.33M -1.85B -27.49M -192M -74.19M -945M -72.43M -70.86M -3.04B	-26.83B -19.72M -17.34M -16.4M -14.87M -27.93M -1.89B -28.1M -196M -75.83M -966M -74.03M -72.43M -3.1B
Net Debt	42.32B 31.1M 27.35M 25.87M 23.46M 44.06M 2.99B 44.32M 310M 120M 1.52B 117M 114M 4.9B	30.76B 22.6M 19.88M 18.8M 17.05M 32.02M 2.17B 32.21M 225M 86.93M 1.11B 84.86M 83.02M 3.56B

CORESTEMCHEMON Inc. Stock

Stocks

A166480

KR7166480004

Biotechnology & Medical Research

Valuation: CORESTEMCHEMON Inc.

Chart: CORESTEMCHEMON Inc.

Latest news: CORESTEMCHEMON Inc.

Quotes and Performance

Price Extremes

Managers and Directors: CORESTEMCHEMON Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes